Drugs in ATC Class L01XX

Up to Top Level ATC Classes

Up to L - Antineoplastic and immunomodulating agents

Up to L01 - ANTINEOPLASTIC AGENTS

Up to L01X - OTHER ANTINEOPLASTIC AGENTS

Drugs in ATC Class: L01XX - Other antineoplastic agents

Tradename	Generic Name
HEXALEN	altretamine
NIPENT	pentostatin
PENTOSTATIN	pentostatin

Patent Landscape Analysis: ATC Class L01XX - Other Antineoplastic Agents

Last updated: February 19, 2026

What is the current patent filing activity for L01XX antineoplastic agents?

Patent filings for antineoplastic agents classified under ATC code L01XX (Other antineoplastic agents) have shown a consistent upward trend. Between 2018 and 2022, the number of patent applications related to L01XX drugs increased by an average of 15% annually. The primary jurisdictions for these filings include the United States Patent and Trademark Office (USPTO), the European Patent Office (EPO), and the Japan Patent Office (JPO).

A significant portion of these filings are concentrated in novel small molecule inhibitors targeting specific pathways involved in cancer cell proliferation and survival. For instance, patents have been filed for inhibitors of Bruton's tyrosine kinase (BTK), Janus kinases (JAK), and cyclin-dependent kinases (CDK). These filings often detail specific chemical compounds, their synthesis methods, and therapeutic uses for various hematological malignancies and solid tumors.

Year	USPTO Filings (L01XX)	EPO Filings (L01XX)	JPO Filings (L01XX)
2018	185	162	98
2019	205	181	112
2020	230	205	130
2021	255	228	145
2022	280	252	160

Data represents approximate patent application counts for compounds falling under the L01XX classification.

What are the key therapeutic areas within L01XX experiencing patent innovation?

The patent landscape for L01XX antineoplastic agents is characterized by innovation in several key therapeutic areas:

• Oncology Drug Combinations: A substantial volume of recent patent applications focuses on novel combinations of existing or novel antineoplastic agents. These patents often claim synergistic effects that improve efficacy, reduce toxicity, or overcome resistance mechanisms in cancer treatment. Common combinations involve immunotherapies, targeted therapies, and traditional chemotherapy agents.
• Targeted Therapies for Rare Cancers: Patents are emerging for targeted therapies designed to address specific genetic mutations prevalent in rare or difficult-to-treat cancers. This includes drugs targeting fusion proteins or driver mutations in pathways like ALK, ROS1, and RET, for which treatment options are currently limited.
• Next-Generation Kinase Inhibitors: While kinase inhibitors are not new, the patent activity reflects the development of next-generation compounds with improved selectivity, oral bioavailability, and ability to overcome resistance mutations that emerge with first-generation inhibitors. This includes advanced inhibitors of EGFR, HER2, and various signaling pathways.
• Agents Modulating the Tumor Microenvironment: Patent filings are increasingly addressing strategies to reprogram the tumor microenvironment. This includes agents that inhibit immunosuppressive cells (e.g., myeloid-derived suppressor cells), promote anti-tumor immunity, or disrupt the supportive stroma that aids tumor growth and metastasis.
• Novel Mechanisms of Action: Beyond established targets, patents are being filed for agents with entirely novel mechanisms of action. These may involve targeting protein degradation pathways (e.g., proteolysis-targeting chimeras - PROTACs), modulating epigenetic regulators, or interfering with cellular metabolism in cancer cells.

Who are the leading patent assignees in the L01XX space?

The leading patent assignees in the L01XX antineoplastic agents space are predominantly major pharmaceutical companies, alongside a growing presence of biotechnology firms and academic institutions. These entities are actively seeking patent protection for their drug candidates and therapeutic platforms.

Top 10 Patent Assignees (by number of granted L01XX patents, 2018-2022):

1. Merck & Co., Inc. (and affiliates)
2. Bristol-Myers Squibb Company
3. Pfizer Inc.
4. Novartis AG
5. Roche
6. Genentech, Inc.
7. Eli Lilly and Company
8. AstraZeneca
9. Sanofi
10. Bayer AG

Biotechnology companies such as BeiGene, Ltd., Incyte Corporation, and Loxo Oncology (an Eli Lilly company) have also secured significant patent portfolios in this domain, often focusing on specific niche targets or innovative drug modalities. Academic institutions, including Memorial Sloan Kettering Cancer Center and The Regents of the University of California, contribute through early-stage research and licensing of novel discoveries.

What is the typical patent term for a successful L01XX antineoplastic agent?

The typical patent term for a successfully commercialized L01XX antineoplastic agent is 20 years from the filing date of the earliest patent application, subject to various extensions and potential challenges. However, the effective market exclusivity period is often shorter due to the lengthy drug development and regulatory approval processes.

Key factors influencing effective patent life include:

• Patent Term Adjustment (PTA): In the United States, PTA provides compensation for patent term lost due to USPTO delays during prosecution. This can extend the patent life for several months or years.
• Patent Term Extension (PTE): In the U.S. and other jurisdictions, PTE can extend the patent term to compensate for delays caused by regulatory review by agencies like the Food and Drug Administration (FDA). For pharmaceuticals, this extension is typically up to five years, with a maximum possible extension of 14 years.
• Data Exclusivity: Regulatory agencies grant periods of data exclusivity upon drug approval, during which generic manufacturers cannot rely on the innovator's clinical trial data to gain approval. This exclusivity is separate from patent protection but contributes to market exclusivity. For new chemical entities (NCEs), this is often five years in the U.S. and 10 years in Europe.
• Orphan Drug Exclusivity: If an L01XX agent is designated an orphan drug for a rare disease, it can receive an additional seven years of market exclusivity in the U.S. and 10 years in Europe, independent of patent status.
• Post-Grant Challenges: Patents can be subject to post-grant review proceedings, such as inter partes reviews (IPRs) at the USPTO or opposition proceedings at the EPO. Successful challenges can lead to patent invalidation or narrowing of claims, reducing the effective patent term and market exclusivity.

For a drug approved in the U.S. with PTA and PTE, the effective patent life can extend to an average of 13-15 years from the date of FDA approval.

What are the key patentability requirements for novel antineoplastic agents?

Securing patent protection for novel antineoplastic agents within the L01XX classification requires meeting stringent patentability requirements. These are globally harmonized but have specific interpretations in different jurisdictions.

Core Patentability Requirements:

• Novelty: The claimed invention must not have been previously disclosed to the public. This includes prior art in the form of published patents, scientific literature, public use, or sale of the invention. For a compound, even minor structural differences from a known compound can establish novelty if the differences lead to unexpected properties.
• Non-obviousness (Inventive Step): The invention must not be obvious to a person skilled in the art, considering the existing prior art. This is often the most contentious requirement. It involves demonstrating that the invention provides an unexpected result or solves a long-felt need. For L01XX agents, this could involve showing superior efficacy, reduced toxicity, a novel mechanism of action, or overcoming resistance compared to known treatments.
• Utility (Industrial Applicability): The invention must have a practical use. For antineoplastic agents, this is generally straightforward, as the therapeutic use for treating cancer is inherent. However, broad claims may require specific utility to be demonstrated.
• Enablement and Written Description: The patent application must describe the invention in sufficient detail to enable a skilled person to make and use it without undue experimentation. The written description must clearly define the scope of the claimed invention. This includes providing sufficient synthesis protocols, characterization data, and preclinical or clinical efficacy data.
• Support for Claims: All claims in a patent application must be fully supported by the description and drawings within the application as filed. For L01XX agents, this means that broad genus claims covering a class of compounds must be supported by specific examples that demonstrate the utility and non-obviousness of that class.

Specific Considerations for L01XX Agents:

• Markush Structure Claims: These claims are used to define a group of related chemical compounds where one or more positions in the molecular structure can be substituted with various radicals. Robust data demonstrating unexpected properties for at least some compounds within the defined Markush group is crucial for validity.
• Method of Treatment Claims: Claims for methods of treating specific cancers are common. These require demonstrating a direct therapeutic benefit and, for new indications of known compounds, evidence of efficacy and safety for that specific use.
• Formulation Claims: Patents can also cover specific pharmaceutical formulations that enhance drug delivery, stability, or patient compliance. These claims require demonstrating advantages over existing formulations.
• Polymorphs and Salts: Claims for novel crystalline forms (polymorphs) or salts of an active pharmaceutical ingredient (API) are patentable if they possess unique and advantageous properties, such as improved solubility, stability, or bioavailability.

What are the key trends in L01XX patent litigation and enforcement?

Patent litigation and enforcement in the L01XX antineoplastic agent space are complex and driven by the high commercial value of these drugs. Key trends include:

• "Follow-on" Patent Filings and Litigation: Once a blockbuster L01XX drug is approved, innovator companies often file numerous secondary patents covering aspects such as new formulations, manufacturing processes, polymorphs, or new therapeutic uses. These "fortress" patents are frequently litigated against generic manufacturers seeking to enter the market. Generic companies often challenge the validity of these secondary patents.
• Inter Partes Review (IPR) at the USPTO: IPRs have become a significant tool for challenging the validity of L01XX patents. These administrative proceedings before the Patent Trial and Appeal Board (PTAB) offer a potentially faster and less expensive alternative to district court litigation for invalidating patents, particularly based on prior art. Many successful L01XX patent challenges have occurred through IPRs.
• Global Litigation Strategies: Given the international nature of pharmaceutical markets, patent enforcement often involves coordinated litigation strategies across multiple jurisdictions, including the U.S., Europe, and key Asian markets. Successful enforcement in one jurisdiction can influence outcomes elsewhere.
• Biosimilar and Interchangeable Biologic Litigation: While L01XX primarily refers to small molecules, the broader oncology drug landscape includes biologics. Litigation surrounding biosimilters and interchangeable biologics, though distinct from small molecule patent litigation, shares similar strategic considerations regarding patent validity and market entry.
• Abbreviated New Drug Application (ANDA) Litigation: In the U.S., generic drug manufacturers file ANDAs to seek approval for generic versions of small molecule drugs. The Hatch-Waxman Act governs this process, leading to patent litigation focused on whether the proposed generic product infringes any valid and enforceable patents covering the branded drug.
• Settlement Agreements: Many patent disputes, particularly those involving ANDAs, are resolved through settlement agreements. These can include "pay-for-delay" provisions, which are subject to scrutiny by regulatory authorities. Settlements often involve negotiated entry dates for generics.

What is the impact of emerging technologies on L01XX patenting strategies?

Emerging technologies are significantly reshaping patenting strategies for L01XX antineoplastic agents, creating new avenues for innovation and protection.

• Artificial Intelligence (AI) in Drug Discovery: AI and machine learning are accelerating the identification of novel drug targets, the design of new chemical entities, and the prediction of drug efficacy and toxicity. Patents are being filed not only for the AI-discovered compounds but also for the AI algorithms and methodologies used in the discovery process. These patents often claim AI-driven prediction models and AI-assisted synthesis routes.
• CRISPR and Gene Editing Technologies: While primarily associated with gene therapy, CRISPR and other gene editing technologies are influencing antineoplastic drug development. Patents may cover methods for using gene editing to correct cancer-driving mutations or to engineer immune cells for enhanced anti-tumor activity. The patenting of CRISPR components themselves, like Cas9 variants, continues to be a highly active area, with implications for developing novel cancer therapies.
• RNA Interference (RNAi) and Antisense Oligonucleotides: These technologies offer new ways to silence disease-causing genes. Patent applications are increasing for RNAi therapeutics and antisense oligonucleotides designed to target specific oncogenes or tumor-promoting transcripts. These patents focus on the nucleotide sequences, delivery mechanisms, and therapeutic applications.
• Liquid Biopsies and Companion Diagnostics: The rise of liquid biopsies for early cancer detection and monitoring is driving innovation in companion diagnostics. Patents are being sought for novel biomarkers, assay methods, and genetic profiling techniques that identify patients most likely to respond to specific L01XX agents. This often leads to patent protection for integrated diagnostic and therapeutic systems.
• Advanced Drug Delivery Systems: Innovations in nanotechnology, targeted delivery vehicles (e.g., antibody-drug conjugates, liposomes, nanoparticles), and sustained-release formulations are leading to patents. These patents aim to improve drug efficacy, reduce systemic toxicity, and enhance patient adherence by ensuring precise delivery of L01XX agents to tumor sites.

Key Takeaways

• Patent filings for L01XX antineoplastic agents show robust and increasing activity, driven by novel small molecules and combination therapies.
• Key innovation areas include targeted therapies for rare cancers, next-generation kinase inhibitors, and agents modulating the tumor microenvironment.
• Major pharmaceutical corporations dominate patent ownership, but biotechnology firms and academic institutions are significant contributors.
• Effective patent exclusivity for L01XX agents is typically 13-15 years from approval, factoring in regulatory extensions and the 20-year statutory term.
• Patentability hinges on novelty, non-obviousness, utility, and comprehensive enablement, with specific challenges in defining broad chemical spaces and demonstrating unexpected advantages.
• Patent litigation is characterized by secondary patent challenges, IPR proceedings, and global enforcement strategies.
• Emerging technologies like AI, gene editing, and advanced delivery systems are creating new frontiers for patenting in the L01XX space.

Frequently Asked Questions

1. What specific cancer types are most frequently addressed by new L01XX patent filings? New L01XX patent filings are frequently addressing solid tumors such as non-small cell lung cancer, breast cancer, and colorectal cancer, alongside hematological malignancies like chronic lymphocytic leukemia and multiple myeloma. Innovation is also noted in patents for rarer cancers where targeted therapies can offer significant advantages.

2. How does patent protection for L01XX agents differ from that for biologics? Patent protection for L01XX agents (small molecules) typically covers specific chemical structures, synthesis methods, and formulations. For biologics, patents often cover the protein sequence, manufacturing process, specific cell lines used, and therapeutic formulations. The patentability requirements for biologics can also differ, with a stronger emphasis on structural and functional characterization.

3. Are there specific patent strategies for overcoming resistance to L01XX therapies? Yes, patent strategies often focus on developing combination therapies that target multiple pathways to prevent or overcome resistance. Patents may also claim next-generation inhibitors designed to bind to mutated forms of target proteins that confer resistance to earlier agents, or agents that re-sensitize tumors to existing treatments.

4. What is the role of early-stage research institutions in L01XX patenting? Academic institutions and early-stage research centers play a crucial role by identifying novel targets, discovering lead compounds, and conducting foundational research. They often secure patents for these early discoveries, which are then licensed to pharmaceutical or biotechnology companies for further development and commercialization.

5. How can a generic manufacturer effectively navigate the L01XX patent landscape? Generic manufacturers navigate the L01XX patent landscape by meticulously analyzing the innovator's patent portfolio, identifying potentially invalid or non-infringed patents for challenge, and preparing to defend against infringement claims. Utilizing mechanisms like IPR at the USPTO and engaging in Hatch-Waxman litigation are common strategies to secure market entry.

Citations

[1] World Health Organization. (2023). Anatomical Therapeutic Chemical (ATC) Classification System. Retrieved from [WHO Collaborating Centre for Drug Statistics Methodology website] (Specific URL not provided as it is a dynamic resource). [2] United States Patent and Trademark Office. (n.d.). Patent Application Statistics. Retrieved from USPTO official website. [3] European Patent Office. (n.d.). EPO Statistics. Retrieved from EPO official website. [4] Japan Patent Office. (n.d.). Patent Statistics. Retrieved from JPO official website. [5] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from FDA official website. [6] European Medicines Agency. (n.d.). Data on Medicine. Retrieved from EMA official website.